← All trials
NCT03994393
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2018
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SydneyLead sponsor
- AstraZenecaCollaborator
- University of New South WalesStudy chair
- Australasian Lung Cancer Trials GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.